Securities code: Shan Dong Kexing Bioproducts Co.Ltd(688136) securities abbreviation: Shan Dong Kexing Bioproducts Co.Ltd(688136) Announcement No.: 2022017 Shan Dong Kexing Bioproducts Co.Ltd(688136)
Announcement of profit distribution plan in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content tips:
Distribution ratio per share: cash dividend of 1 yuan per 10 shares
The profit distribution is based on the total share capital registered on the equity distribution registration date, and the specific date will be specified in the equity distribution implementation announcement.
If the total share capital of the company changes before the equity registration date of equity distribution, the company plans to maintain the total distribution unchanged, adjust the dividend proportion per share accordingly, and will announce the specific adjustment separately.
The proportion of cash dividends in this year is less than 30%, which is mainly due to the fact that the company combines the characteristics of the industry and the development stage of the company, and fully considers the capital needs such as R & D, production line construction and market development in 2022.
1、 Contents of profit distribution plan
Audited by Dahua Certified Public Accountants (special general partnership), the net profit attributable to the shareholders of the listed company in 2021 was 9646391426 yuan, and the distributable profit of the parent company was 16277571979 yuan as of December 31, 2021. In 2021, the company plans to distribute profits based on the total share capital registered on the date of equity distribution. The profit distribution plan is as follows:
The company plans to distribute a cash dividend of 1 yuan (including tax) to all shareholders for every 10 shares. As of december312021, the total share capital of the company is 198700650 shares. Based on this calculation, the total cash dividend to be distributed is 1987006500 yuan (including tax). The total cash dividends of the company in this year accounted for 20.60% of the net profit attributable to the owners of the parent company in the consolidated statements.
If the total share capital of the company changes before the equity registration date of equity distribution, the company plans to maintain the total distribution unchanged, adjust the distribution proportion per share accordingly, and will announce the specific adjustment separately.
This profit distribution plan needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation.
2、 Description of cash dividend ratio less than 30% in this year
The company attaches importance to the reasonable return on investment to investors and formulates profit distribution policies in strict accordance with the requirements of relevant laws and regulations. According to the articles of association and the dividend return plan for shareholders in the first three years after listing, the annual profit distributed by the company in cash shall not be less than 10% of the distributable profit realized in that year. Considering the company's current industry development and the company's future capital demand, the company puts forward the profit distribution plan for 2021, which not only protects the legitimate rights and interests of investors, but also takes into account the company's sustainable and stable development needs. The total cash dividends to be distributed by the company this time account for less than 30% of the net profit attributable to the shareholders of the listed company this year. The specific reasons are as follows:
(I) industry situation and characteristics of the company
2021 is the first year of the 14th five year plan. National policies support biomedicine in a high frequency, multi-level and all-round way, incorporate biomedicine into the 14th five year plan, further guide enterprises to break through core technologies, strengthen key core technologies and product research by relying on major science and technology projects and high-quality development projects of manufacturing industry, strengthen international cooperation in the field of technology, and effectively solve the problem of "bottleneck", In order to provide strong support for building a modern economic system and realizing high-quality economic development, the biomedical industry has ushered in great opportunities.
By virtue of policy, talent and capital dividends, China's innovative research and development of biological drugs has entered the acceleration stage. The successful realization of listed products has boosted the further expansion of the market scale of biological drugs, the output of domestic innovative drugs has accelerated significantly, China's new drug research and development has moved from imitation innovation to original innovation, and more products and services of Youxiu biomedical enterprises have moved towards globalization.
(II) development stage of the company and its own business model
The company is one of the leading enterprises in the field of recombinant protein biopharmaceuticals in China. It focuses on drug research and development in the treatment fields of antiviral, tumor and immunity, blood, digestion and degenerative diseases. It has the ability of pharmaceutical innovation in the whole process from drug discovery, pharmaceutical research, preclinical research, clinical research to industrialization.
According to the company's current development stage and overall business objectives, the company needs to invest a large amount of funds in R & D, capacity expansion and product market development to achieve stable growth in business performance.
(III) profitability and capital demand of the company
In 2021, the company realized an operating revenue of 128517172890 yuan, a net profit attributable to shareholders of listed companies of 9646391426 yuan, and a R & D investment of 12295081498 yuan, an increase of 104.54% year-on-year. The company has developed steadily and its business performance continues to improve.
In the future, the company will fully promote the R & D of products under research, actively expand cooperation with leading R & D institutions at home and abroad, and accelerate the introduction of mature and high-value products and advanced technology by means of technology transfer, cooperative development and commercial cooperation. The company will continue to focus on key tracks such as anti-tumor and autoimmunity, accelerate the introduction of heavy products for domestic and export, and constantly strengthen the construction of Chinese and international marketing network system to realize long-term operation of the enterprise. Therefore, the company has a large capital demand in the future.
(IV) reasons for the low level of cash dividends of the company
The company attaches great importance to the return of shareholders, combines the characteristics of the industry and the needs of business development, comprehensively considers the overall strategic layout and capital needs of the company, steadily and orderly promotes R & D, technology, expansion, market and other work, ensures the sustainable and stable development of the company's operation, and prudently puts forward the profit distribution plan for 2021, which takes into account the development of the company and the interests of shareholders.
(V) the exact purpose of retained undistributed profits and the estimated income of the company
The retained undistributed profits of the company will be transferred to the next year, which will be mainly used for R & D investment, capacity expansion projects and business development. The expansion of the company's scale and the improvement of profitability are conducive to bringing long-term returns to investors. The income level related to retained undistributed profits of the company is affected by many factors, such as macroeconomic situation, changes in asset quality, asset interest rate and so on.
3、 Decision making procedures performed by the company
(I) convening, deliberation and voting of the board meeting
The company held the 32nd meeting of the first board of directors on April 15, 2022, reviewed and approved the proposal on the company's 2021 annual profit distribution plan, agreed to the profit distribution plan and agreed to submit the plan to the company's 2021 annual general meeting for deliberation.
(II) opinions of independent directors
Independent opinions of independent directors on the rationality of low cash dividend level: the company's annual profit distribution plan for 2021 complies with the relevant provisions of the company law and the articles of association, comprehensively analyzes the industry environment, the company's current profitability and the actual situation of capital demand in the process of operation and development, takes into account the interests of all shareholders, is conducive to the stable development of the company, and does not harm the company, shareholders Especially the legitimate rights and interests of minority shareholders.
In conclusion, we agree with the company's profit distribution plan and agree to submit the proposal to the company's 2021 annual general meeting for deliberation.
(III) opinions of the board of supervisors
The company held the 18th meeting of the first session of the board of supervisors on April 15, 2022 and considered and approved the proposal on the company's profit distribution plan for 2021. The board of supervisors held that the company's profit distribution plan for 2021 fully considered the company's profitability, cash flow and capital demand, which was conducive to the sustainable and stable development of the company and did not harm the interests of the company and its shareholders, especially small and medium-sized shareholders. The board of supervisors unanimously agreed to the 2021 profit distribution plan and agreed to submit the proposal to the 2021 annual general meeting of shareholders of the company for deliberation. 4、 Relevant risk tips
(I) this profit distribution plan combines the company's development stage, future capital demand and other factors, and will not have a significant impact on the company's operating cash flow, normal operation and long-term development.
(II) this profit distribution plan can only be implemented after being submitted to the 2021 annual general meeting of shareholders of the company for deliberation and approval. Please pay attention to the investment risks.
It is hereby announced.
Shan Dong Kexing Bioproducts Co.Ltd(688136) board of directors April 19, 2022
